Method of inactivating lipid-enveloped viruses

Patent 6136321 Issued on October 24, 2000. Estimated Expiration Date:

February 10, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Inventors

Assignee

Baxter Aktiengesellschaft

Application

No. 021146 filed on 02/10/1998

US Classes:

424/208.1, Immunodeficiency virus (e.g., HIV, etc.)424/184.1, ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)435/235.1, VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING435/236, Inactivation or attenuation; producing viral subunits435/238, By chemical treatment435/239Recovery or purification

Examiners

Primary: Budens, Robert D.

Attorney, Agent or Firm

Foley & Lardner

Foreign Patent References

0 037 931 EP. 10/13/1981
0 564 958 EP. 10/13/1993
37 04 550 DE. 08/13/1988
93/01831 WO. 02/13/1993

International Classes

A61K 039/12
C12N 007/06

Foreign Application Priority Data

1997-02-24 AT

Abstract

The invention relates to a method of inactivating lipid-enveloped viruses by means of a non-ionic detergent, and the preparation of a vaccine containing the inactivated virus. The invention further relates to an inactivated virus which is characterized by its structural integrity, in particular the structural integrity of its enveloping proteins, as well as to the use of the inactivated virus for preparing a vaccine.

Other References

Haraud, "Introductory Remarks: Viral Safety Of Biologicals", Develop. Biol. Standard, vol. 75:3-7, (1991)
Brown, "Review Of Accidents Caused By Incomplete Inactivation Of Viruses", Develop. Biol. Standard, vol. 81:103-107, (1993)
Smith et al., "Laboratory Aspects Of Fourteen Human Cases Following Vaccination And Attempts To Isolate The Virus From The Vaccine", Am. J. Hyg., vol. 63:150-164, (1956)
Mussgay et al., "Preparation Of Inactivated Vaccines Against Alphaviruses Using Semliki Forest Virus--White Mouse As A Model", Intervirology, vol. 1:259-268, (1973)
Piet et al., "The Use Of Tri(n-butyl)phosphate Detergent Mixtures To Inactivated Hepatitis Viruses And Human Immunodeficiency Virus In Plasma And Plasma's Subsequent Fractionation", Transfusion, vol. 30(7):591-598, (1990)
Danihelkova et al., "Disruption Of Influenza Virus A By Diethylether-tween and Tri-N-Butyl Phosphate-tween Mixtures", Acta Virol., vol. 28:26-32, (1984)
Gross et al., "Comparison Of New Triton X-100-and Tween-Ether-Treated Split-Product Vaccines In Children", Journal Of Clinical Microbiology, vol. 14(5):534-538, (1981)
Hennig et al., "Immunization with Tween-Ether-Treated SIV Adsorbed Onto Aluminum Hydroxide Protects Monkeys Against Experimental SIV Infection", Virology, vol. 186:588-596, (1992)
Reed et al., "A Simple Method Of Estimating fifty Per Cent Endpoints", The Journal of Hygiene, vol. 27(3):493-497, (1938)
Laemmli, "Cleavage Of Structural proteins During The Assembly Of The head of Bacteriophage T4", Nature, vol. 277:680-685, (1970